Jiangsu

Jiangsu's financial sector consolidation is advancing with a proposed merger between Soochow Securities and Donghai Securities, valued at 11.52 billion yuan. The deal highlights regional integration efforts in China's second-largest provincial economy.

China’s Innovent Biologics has signed a $10.5 billion global collaboration with Pfizer to develop 12 cancer treatment programs. The deal includes an upfront payment of $650 million and potential milestone payments totaling up to $9.85 billion.

Innovent Biologics and Pfizer have signed a $10.5 billion collaboration to develop 12 cancer treatment programs. Innovent will receive an upfront payment of $650 million and up to $9.85 billion in milestone payments tied to development, regulatory, and commercial goals.